Joana and Officer. Chief me Maynard, With Thanks, Financial; afternoon, Chief our today Ryan and are good Matt, everyone. Dr. Goncalves, Medical our
questions. treatment I the executing of and a chronic our will financial difelikefalin. be First, After and want will injection Then, the world quick progress latest will in the that into give in your development pruritus. a to XXXX for our strategy the significant to overview of launch KORSUVA leader to share become I progress update. take available Ryan insights our progress follow with the oral we
be treatments. for it often currently problem patients. of and can category second a quality In defining of to in is lack in injection have diseases, our condition. remains underserved new treatment a in KORSUVA forward this significant a light leader chronic patients pruritus pruritus on propelled of launch severe, is of of treatment pruritus options, a it the of used journey this impact XXXX in in Chronic wide quarter though range millions chronic the the by the rang of care U.S. negative The era and for intractable of even life of underreported,
We the of the treatment for disease are science and the that this most committed care to patients our enhancing awareness so possible. improving benefits protocols patient novel
stage expanding adoption the franchise around in target Enrollment in CKD late differentiated of and the nephrology year, dermatology. nephrology our Over made establishing in partner great and our franchise. in data patients. we difelikefalin into on nephrology franchises program of two Moreover, trial and this oral and the we we the strides the countries The with the and dependent translating and mission action top our world. Vifor, the Together our the driving non-dialysis half progressing second and foundation XXXX. is U.S. core for laser injection created to well, commercial in launch past continue are KORSUVA focused release for with firmly are promising we CSL line
well. oral itch Switching XXXX. kind of of franchise, second a continue dermatology franchise. positive is of to paresthetica program a dermatitis track X The to our our atopic in us gives a Phase our target the in in AD. half to distinct difelikefalin readout progressing And our results enrollment truly can hypothesis, program our pruritus one-two of punch in opportunity but a internal only stage not also notalgia that complement dermatology created one independent to of confirmed late the origin unique to build This we difelikefalin
published the X/X recognition Journal from results. Medicine the the New which in launch about recently our program of We England Phase and Phase are excited of NP X our
more on some strategic provide the me priorities franchises. two quarter Now, within the and of let progress our the details
the KORSUVA progress U.S. we the in of First, making launch meaningful are injection, on
quarter revenue to XX,XXX to clinics for of and were sales million fourth vials. us, wholesaler XXXX, into as For approximately the dialysis KORSUVA of net totaled injection $X.X shipments recorded translating profit million, $X.X
This the trial quarterly dynamics both have to certain see orders the in ecosystem and accelerating. performance the inventory phase. from third and clinics After a and adoption drawn of the started quarter, we and initial performance to the unique being is based represents launch stocking wholesaler at reflective building in down this transition and and phase the second demand inventory
are two months pleased momentum first We to see continuing through of the this XXXX.
providers KORSUVA is from in KORSUVA positive. promise to performing on on it the highly And been feedback and the we important, studies continue as expected. clinical delivering and patients as has that Equally we hear demonstrated
the push break the with the are commitment out of long-term by rapid KORSUVA adoption. me KORSUVA with dynamics the we at FMC Let promotion as Starting Fresenius, in the various addition field for of different to DOs. force the and the of reflected FMC success from its pleased both the
the in its stock priority, its of In approach network. clinics quarter care as product most a and with facilitate their to third one non-traditional took number patient across Fresenius trial
dynamic. initial FMC’s move the from While we saw medical growth reorders, value In steady the in placing of FMC unmet and demonstrates belief KORSUVA's need reflection inventory a in number in proposition, it adoption. their an this utilizing confidence of created and atypical a clear fourth clinics trial to in CKD-associated strategy pruritus the inventory quarter, their
first very during and of there is in what is accelerated start exceeded already XXXX. volume in strong wholesalers of from repeat clinics entire clinic eight positive this a XXXX. when quarter reorders the and have fourth the customers. using buy encouraging, the weeks has clinics order KORSUVA, become FMC This trend year, these Encouragingly put, the Simply in
utilized in be by will FMC to ahead, expect expect Looking And the we inventory see reordering. across inventory as trial of FMC we mid-XXXX. the their clinic and shifts clinics of growth continued to adoption the the network, most number at utilizing level
number DaVita, order KORSUVA. steady At see in growth the we in of clinics
to that have continue this with reorder we clinics see a which experience For rate, a high KORSUVA purchased suggests clearly positive product. those
to up initiatives the We Vifor down KORSUVA with work bottom clinics. of accelerate continue top to DaVita and adoption CSL at on
and IDO front, strong, as ordering terms MDO as clinics both the reorder in be well of number the rates. uptake to the continues On of
less XX%, of segment market of progress that providers underscores we feel experience with this at the and than represents patients positive the While these KORSUVA. organizations the
wholesaler mid-XXXX. dynamics related not uptake to that To summarize, shipped inventory we normal and vial given the specifically, any to the a anticipate future the clinic More significant level. stocking launch more sales quarters, we for few be clinics the expect during emerge will curve KORSUVA and dialysis to or first at
clinic to the the it is demand. and However, important patient of that inventory represent level true is is at wholesaler at shipments combination it draw-downs depleted, emphasize to new together clinics clinics remaining inventory the that until the
Overall, KORSUVA. we long-term encouraged the in potential by are progress remain we in the of confident U.S. the launch and
access in we next and the XX in international of XXXX. consortium U.S. the once come progressing Kapruvia the XXXX, continues line patient momentum. in to commence very the is most expect rollout in and testimonials other the front, gain XX the all in received expect encouraging and On have of Launches Denmark feedback countries product approved four four Furthermore, well in Germany, first with reimbursement are Europe The in Switzerland online Singapore and is the we to the in to to of initial these and we Austria, Sweden in countries secured and launches countries, months. provider Canada, Australia, countries the Europe
to we positive of on continue with XXXX XXXX. of Based expect a in in Japan half in and the submission the interactions the regulatory the PMDA, second regulatory decision half second
product the will partner approved if reminder, is milestone payment Japan, we from receive a a As Maruishi. in our
exclusive the commercialization of China. The co-development and KORSUVA JV of also recently licensing for agreement with FMC Winhealth and CSL signing a Vifor announced long-term in
very near-term. to starting are we this development positive We and look by the excited in work forward
the of proposed the in patients. post for utilization that of for designation Lastly, KORSUVA second on payment CMS post rule of payment further drug TDAPA adequate calendar its period. linking We issued of outlined mechanism generally for would reimbursement regarding believe the briefly payment mechanisms RFI quarter let TDAPA RFI touch with We concept to an in the as appropriate the XXXX, support different me period. expiration appropriate the provide XXXX, drugs part the TDAPA In year the an TDAPA. drug
other clear to update visibility We have to do support work of as during exact in stakeholders continue CMS a rulemaking from cycle. CMS TDAPA and closely with continue a positive post its substantive not to regarding timing while this mechanism, we the to the hope for we decision And decision-making year's process. final reimbursement
to on pipeline. our Moving
our associated difelikefalin dependent through therapeutic we expand We franchises in non-dialysis XXXX work X year, second difelikefalin. our are pruritus half XXXX. of as we and Phase the well Last advanced program CKD well utility progressing is building with launched results of and oral programs programs to both AD both the the in top in of program Enrollment of for for in first the CKD dermatitis. atopic the as expect line half two
to continue track the KIND Phase study. X XXXX A half of readout internal the of X to We for second of the part
with the data difelikefalin program fourth in the we cleared In year, interaction in which path X oral positive the had last notalgia reported X/X FDA, positive Additionally, of we Phase Phase initiating our from paresthetica. our to a quarter trial XXXX, NP. of
maximize as to program, the and to we rapidly for Like operational AD goal studies our with the the the possible enhance program NP efficiency our to success. designed potential advance as
the dose of portion the the the study the second finding results XXXX, in XXXX. of program KOURAGE expect in for with internal of We readout half top-line half final the X of first
believe year In XXXX we was Cara. for pivotal conclusion, a
the promising future laid the company. stakeholders progress for and growth our Our for of foundation sustained value-creation our and
year On expected and the the launch. variability KORSUVA over fluctuating first injection dynamic launch, a we of
trends of and in positive in uptake KORSUVA injection. confident the long-term seeing are remain potential product We
significant our and the demonstrating underway, toward programs difelikefalin. potential therapeutic establishing late-stage franchises of maximizing three have We progress two
to results. to I and to on over quarter would full fourth for details year Ryan. like turn you our now additional Ryan it Over
